The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 59 | — | 20.1x | Near average | |
Growth | 74 | — | 5.6% | Above average | |
Quality | 19 | -43.9% | 7.6% | Below average | |
Safety | 65 | 3.3x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | 43 | — | — | Near average | |
Sentiment | 38 | — | — | Near average |
Monopar Therapeutics Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Monopar Therapeutics Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
MNPR stock has experienced a gradual decline in the average target price over the past thirty days, with the consensus dropping from $119 to $110, representing a 7.56% decrease. Despite this reduction, the current target price ($110) still reflects significant optimism compared to the current trading price of $60.56, with low dispersion among analysts (range between $105 and $115), indicating relative agreement on the expected fair value despite the lowered estimates.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.